25
Jul
2024

PBMs Feel the Heat, Megarounds Abound, and the XBI Tops 100

Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $199 per year, you reward quality independent biotech reporting, and encourage more.

 
 

You may also like

Aliada’s Mega Return, GSK & AbbVie Eye T-Cell Engagers, and IPO Scorecard
Intellia In Vivo Disappoints, Seaport Aims at Anxiety, & Wave Shows RNA Editing Promise
Nobel for Protein Design and AlphaFold, Scholar Rock Shines, and a City is Born
BioAge Goes Public, Kailera Piles into GLP-1, and Lilly Bets Big on Indiana